RMD vs SOLV: stock comparison and AI forecast
Resmed Inc (RMD) and Solventum Corp (SOLV) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
RMD Resmed Inc
- Price
- $235.30 +13.7% · 6M
- Market Cap
- $33.10B
- P/E Ratio
- 21.4x
- Size
- large-cap
- AI Forecast
SOLV Solventum Corp
- Price
- $87.18 +21.7% · 6M
- Market Cap
- $14.84B
- P/E Ratio
- 80.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- RMD is 2.2 times larger than SOLV by market capitalization ($33.10B against $14.84B).
- RMD trades at 21.4 times trailing earnings, SOLV at 80.7 times.
- Over the last six months SOLV returned +21.7% and RMD +13.7%.
- RMD turns 27.8% of its revenue into net income, against 1.9% for SOLV.
- SOLV carries 1.95 times debt per unit of equity, against 0.38 times for RMD.
- RMD yields 1.08% in dividends; SOLV pays none.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | RMD | SOLV |
|---|---|---|
| Market Cap | $33.10B | $14.84B |
| P/E Ratio | 21.43x | 80.72x |
| P/B Ratio | 5.56x | 3.09x |
| Dividend Yield | 1.08% | – |
| EPS | $10.98 | $1.08 |
| Book Value/Share | $42.29 | $28.23 |
| Revenue/Share | $40.76 | $47.95 |
| FCF/Share | $11.44 | $0.00 |
Profitability & Margins
| Metric | RMD | SOLV |
|---|---|---|
| ROE | 26.8% | 3.2% |
| ROA | 19.4% | 1.1% |
| ROIC | 27.5% | 4.3% |
| Gross Margin | 61.1% | 54.8% |
| Operating Margin | 33.0% | 5.6% |
| Net Margin | 27.8% | 1.9% |
| EBT Margin | 35.1% | 2.1% |
| Tax Rate | 20.8% | 8.2% |
Financial Health
| Metric | RMD | SOLV |
|---|---|---|
| Current Ratio | 2.65x | 1.03x |
| Quick Ratio | 1.88x | 0.72x |
| D/E Ratio | 0.38x | 1.95x |
| Financial Leverage | 1.38x | 2.95x |
| Interest Coverage | 99.0x | 0.3x |
| Working Capital | $2.18B | $117M |
Cash Flow
| Metric | RMD | SOLV |
|---|---|---|
| Operating Cash Flow | $1.77B | $310M |
| Free Cash Flow | $1.61B | $0.00M |
| Capital Spending | -$162M | -$310M |
| OCF Growth YoY | -6.0% | -37.1% |
| FCF Growth YoY | -9.0% | -100.0% |
| FCF/Sales | 28.1% | 0.0% |
| CapEx/Sales | 2.8% | 3.8% |
Operational Efficiency
| Metric | RMD | SOLV |
|---|---|---|
| Asset Turnover | 0.70x | 0.58x |
| Receivables Turnover | 5.9x | 6.0x |
| Inventory Turnover | 2.2x | 3.4x |
| Fixed Assets Turnover | 9.5x | 5.9x |
| Days Sales Outstanding | 62 days | 61 days |
| Days Inventory | 167 days | 109 days |
| Payables Period | 52 days | 80 days |
| Cash Conversion Cycle | 177 days | 90 days |
Income Statement
| Metric | RMD | SOLV |
|---|---|---|
| Total Revenue | $5.73B | $8.16B |
| Operating Income | $1.89B | $455M |
| Net Income | $1.59B | $156M |
| R&D Expense | $394M | $722M |
| SG&A Expense | $1.18B | $3.33B |
| Cost of Goods Sold | $2.23B | $3.69B |
Dividend & Shareholder Information
| Metric | RMD | SOLV |
|---|---|---|
| Dividends Per Share | $2.54 | – |
| Payout Ratio | 23.1% | – |
| Shares Outstanding | 141M | 170M |
| Net Income Growth | 10.8% | -89.8% |
| EPS Growth | 12.4% | -86.3% |
RMD vs SOLV: stock comparison and AI forecast
Which is bigger, RMD or SOLV?
RMD is 2.2 times larger than SOLV by market capitalization ($33.10B against $14.84B).
Which is cheaper on earnings, RMD or SOLV?
RMD trades at 21.4 times trailing earnings, SOLV at 80.7 times.
Which stock performed better over the last six months, RMD or SOLV?
Over the last six months SOLV returned +21.7% and RMD +13.7%.
Which one does Intratio's AI model rank higher, RMD or SOLV?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.